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Objectives This study sought to compare health status and quality-of-life outcomes for patients with severe aortic stenosis
(AS) and high surgical risk treated with either transcatheter aortic valve replacement (TAVR) or surgical aortic
valve replacement (AVR).
Background For high-risk patients with severe AS, TAVR has been shown to result in similar 12-month survival but differing
adverse events compared with AVR.
Methods We evaluated the health status of 628 patients with severe, symptomatic AS at high risk of surgical complications
who were randomized to either TAVR or AVR in the PARTNER Trial. Health status was assessed at baseline and 1, 6,
and 12 months using the Kansas City Cardiomyopathy Questionnaire, the Short Form-12, and the EuroQol-5D.
Results The primary outcome, the Kansas City Cardiomyopathy Questionnaire summary score, improved more rapidly
with TAVR, but was similar for the 2 groups at 6 and 12 months. However, there was a significant interaction
between the benefit of TAVR and access site (transapical vs. transfemoral). Patients eligible for transfemoral
TAVR demonstrated significant health status benefits with TAVR versus AVR at 1 month (difference, 9.9 points;
95% confidence interval: 4.9 to 14.9; p  0.001), whereas patients treated via the TA approach demonstrated
no benefits with TAVR compared with AVR at any time point. Results for Kansas City Cardiomyopathy Question-
naire subscales and generic measures demonstrated similar patterns.
Conclusions In high-risk patients with severe AS, health status improved substantially between baseline and 1 year after either
TAVR or AVR. TAVR via the transfemoral, but not the transapical route, was associated with a short-term advantage
compared with surgery. (Placement of AoRTic TraNscathetER Valve [PARTNER] trial; NCT00530894) (J Am Coll Car-
diol 2012;60:548–58) © 2012 by the American College of Cardiology Foundation
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August 7, 2012:548–58 Quality of Life After TAVR Versus AVRFor decades, surgical aortic valve replacement (AVR) has
been the only effective therapy for severe aortic stenosis
(AS). AVR improves on the otherwise very poor natural
history of severe, untreated AS (1) and also relieves symptoms and
improves quality of life (QOL) to age-adjusted population norms,
even among elderly patients (2,3). More recently, transcatheter
AVR (TAVR), which can be performed using 1 of several
access sites including a percutaneous transfemoral (TF) arterial
approach (4) or by direct transapical (TA) puncture of the left
entricle via a limited anterior thoracotomy (5), has been
eveloped as a less invasive alternative to AVR. TAVR has
een shown to improve QOL in several nonrandomized series
5–7) and to greatly improve both survival (8) and QOL (9)
ompared with standard therapy in patients who are not
andidates for surgery.
Recently, in a population of AS patients at high risk of
dverse surgical outcomes, the PARTNER (Placement of
oRTic TraNscathetER Valve) trial Cohort A demon-
trated similar 12-month survival among patients random-
zed to either TAVR or AVR (10). Periprocedural adverse
vents differed between TAVR and AVR, however, with some
e.g., cerebrovascular and vascular complications) occurring
ore frequently with TAVR and others (major bleeding,
ew atrial fibrillation) occurring more frequently with sur-
ery. Other 12-month outcomes were generally similar. In
ddition, TAVR was associated with a higher incidence of
aravalvular regurgitation (10), which may have adverse
hort- and long-term health consequences (11).
In light of these observations, a more complete under-
tanding of the impact of these alternative approaches to
ortic valve replacement on health status (which includes
ymptoms, functional status, and QOL) (12), as assessed
rom the patient’s perspective, may be relevant for clinical
ecision making. To address these questions, we conducted
prospective evaluation of health status after either TAVR
r AVR as part of the PARTNER trial.
ethods
tudy design. The design of the PARTNER trial along
ith a full list of inclusion and exclusion criteria was
eported previously (8,10). The PARTNER program
creened 3,105 patients with severe, symptomatic AS at 25
tudy centers (22 in the United States). Severe AS was
efined as an aortic valve area of 0.8 cm2 with either a
ean valve gradient of at least 40 mm Hg or a peak velocity
f at least 4.0 m/s. In addition, all patients were required to
e at high risk of operative complications with an expected
isk of perioperative mortality of 15% (as determined by 2
urgeons at the study center and the study’s executive
ommittee).
Once a patient was deemed appropriate for inclusion in
he trial, but before randomization, a detailed assessment of
he iliofemoral and aortic anatomy was performed to deter-
ine whether the patient was suitable for TAVR via the TFpproach. Those patients found to be suitable for the TF (pproach were then randomized
o TF TAVR versus AVR (TF
ohort), whereas those patients
ho were not suitable for a TF
pproach were randomized to
ransapical TAVR versus AVR
TA cohort).
easurement of health sta-
us. Health status was evaluated
n all patients using validated
ritten questionnaires at baseline
nd 1, 6, and 12 months after
andomization. Baseline ques-
ionnaires were completed at the
nrolling centers before random-
zation. Follow-up question-
aires were administered during
cheduled follow-up visits at the
nrolling centers or by mail. Val-
dated translations of the original questionnaires were pro-
ided to non-English speakers.
The Kansas City Cardiomyopathy Questionnaire (KCCQ)
as used to assess disease-specific health status, and its
verall summary score was defined prospectively as the
rimary endpoint for this analysis. The KCCQ is a 23-item
uestionnaire designed and validated to evaluate self-
eported health status in patients with heart failure (13).
he conceptual domains of the KCCQ include symptoms,
hysical limitation, social limitation, self-efficacy, and
OL. These scales, as well as an overall summary scale, are
cored from 0 to 100, with higher scores indicating fewer
ymptoms and better QOL. KCCQ summary scores have
reviously been shown to correspond roughly with New
ork Heart Association functional class as follows: class I, a
core of 75 to 100; class II: 60 to 74; class III: 45 to 59; and
lass IV: 0 to 44 (14). The KCCQ has been shown to
ndependently predict mortality and health care costs in
eart failure populations (15,16). Among outpatients with
eart failure, small, moderate, or large clinical improve-
ents as rated by treating physicians corresponded with
hanges in the KCCQ summary score of approximately 5,
0, and 20 points (14).
Generic health status was evaluated with the Medical
utcomes Study Short-Form 12 (SF-12) questionnaire (17)
nd the EuroQol (EQ-5D) (18). The SF-12 was derived
rom the larger Short Form-36 questionnaire, one of the
ost extensively validated and most frequently used generic
OL measures; the physical and mental summary scores
btained from the SF-12 correlate highly with those calcu-
ated using the original longer questionnaire (17). These
ummary scores are scaled to an overall U.S. population
orm of 50  10; higher scores are better. Minimum
linically important differences on the SF-12 summary
cales are 2 to 2.5 points (19,20). The EQ-5D is a generic
ealth state classification system comprising 5 domains
Abbreviations
and Acronyms
AS  aortic stenosis
AVR  aortic valve
replacement
CI  confidence interval
EQ-5D  EuroQol
KCCQ  Kansas City
Cardiomyopathy
Questionnaire
QOL  quality of life
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EQ-5D have been transformed to preference-based utilities
based on responses from a U.S. reference population (21).
These utilities take on possible values ranging from 0 to 1,
with 1 representing ideal health and 0 representing the
worst imaginable health state (usually death).
Statistical analysis. Patients with missing baseline KCCQ
scores were excluded from our analysis because both within-
group and between-group statistical comparisons were ad-
justed for baseline values. The remaining patients made up
the analytic population for our study. All patients were
grouped according to their randomized treatment assign-
ment in accordance with the intention-to-treat principle. A
secondary analysis was performed after excluding 21 subjects
who did not undergo their assigned treatment (as-treated
population).
Summary measures for the KCCQ, SF-12, and EQ-5D
were generated using the scoring algorithms published by
their developers (13,21,22). Patients’ baseline characteristics
and baseline KCCQ, SF-12, and EQ-5D scores were
compared between groups using 2-sample Student t tests for
continuous variables and chi-square tests for categorical
variables. Mean changes from baseline within each of the
treatment groups at 1, 6, and 12 months were estimated for
each of the health status measures and tested for significance
using paired Student t tests. These analyses allowed us to
estimate the extent of improvement from baseline after both
TAVR and AVR at different points during the first year of
follow-up.
For each of the primary and secondary QOL outcomes,
longitudinal random-effects growth curve models were used
to examine the relative impact of TAVR versus AVR over
time (23). These growth curve models used available QOL
data from all follow-up time points (1, 6, and 12 months)
and adjusted for baseline score as well as age, sex, and
oxygen-dependent chronic obstructive pulmonary disease.
The models also included the TAVR access site (TF vs. TA
cohort) and treatment assignment, as well as the interaction
between these factors, as covariates. The analytic plan
specified that if a significant (p  0.05) interaction between
reatment and procedural approach was observed on the
CCQ summary score at any time point, then all QOL
utcomes would be analyzed separately for the TF and TA
roups. Linear and quadratic effects of time were considered
s well as all 2- and 3-way interactions between treatment,
ime, and TAVR access site. Starting with the highest order
ime-by-treatment interaction, variables were retained in
he model if p  0.05 using a backward elimination
rocedure. Estimates of differences in mean scores between
reatment groups at each follow-up time point along with
heir associated confidence intervals (CIs), and p values were
btained from the growth curve models. To address the
otential impact of missing data on our results, we repeated
he growth curve models after imputing worst case values
defined as the 10th percentile response for a given time
oint) for surviving patients with missing scores. pTo provide further clinical perspective on changes in
health status over time, we derived categorical variables for
the change in the KCCQ summary score from baseline to
each follow-up time point. For these analyses, we defined 6
ordinal categories based on previously established thresholds
for clinically relevant change (14): dead; worse (decrease
from baseline of 5 points); unchanged (change between
5 and 5 points); slightly improved (increase between 5 and
10 points); moderately improved (increase between 10 and
20 points); and substantially improved (increase 20
points). We then compared the relative impact of TAVR
versus AVR using ordinal logistic regression, with treatment
group, TAVR access site, and the 2-way interaction be-
tween these variables as covariates.
All analyses were performed using SAS version 9.2 (SAS
Institute, Cary, North Carolina). All p values are 2 tailed,
and p 0.05 was used to denote statistical significance in all
cases, with no adjustments for multiple comparisons.
Results
Patient population and baseline health status. Of the
99 patients randomized to TAVR or AVR in the
ARTNER trial, 628 completed baseline health status
uestionnaires and were included in our analysis. The
aseline characteristics of these patients, stratified by TAVR
rocedural approach (TF cohort, n  446; TA cohort, n 
82), are shown in Table 1. As previously reported, the
ARTNER trial patients were elderly (mean age, 83 years)
ith a high burden of both cardiac and noncardiac comor-
id conditions. As expected, patients who were ineligible for
he TF approach and thus randomized within the TA
ohort were more likely to have cerebrovascular disease,
eripheral artery disease, and previous coronary artery by-
ass graft. The baseline characteristics of the patients
andomized to TAVR and AVR were well balanced in both
he TF and TA subgroups. The 71 patients who did not
omplete the baseline questionnaires and were therefore
xcluded were slightly older, but otherwise similar to the
atients included in our analysis (Online Table 1).
Baseline KCCQ, SF-12, and EQ-5D scores are also
hown in Table 1. The overall population had a mean
aseline KCCQ summary score of 41.9, a value that is
enerally consistent with New York Heart Association class
V heart failure. Mean baseline SF-12 physical scores were
0.2, 2 SDs below the overall mean for the U.S. popula-
ion, and baseline mental scores were 47.2. Mean baseline
Q-5D scores were 0.67. In both the TF and TA cohorts,
light imbalances in the baseline scores were seen, with
ean KCCQ scores 3 to 6 points lower among patients
andomized to TAVR, depending on the subscale, and
ean SF-12 scores 1 to 2 points lower. Baseline scores were
imilar in the TF and TA cohorts.
ithin-group comparisons. Follow-up questionnaires
ere obtained from80% of surviving subjects at each time
oint, with slightly more missing data in the AVR than the
v Societ
t
551JACC Vol. 60, No. 6, 2012 Reynolds et al.
August 7, 2012:548–58 Quality of Life After TAVR Versus AVRTAVR patients (Online Table 2). Within-group changes
between baseline and 1-, 6-, and 12-month follow-up for
each health status measure, stratified by access site, are
shown in Tables 2 (TF cohort) and 3 (TA cohort). Both
TAVR and AVR subjects, regardless of procedural ap-
proach, demonstrated substantial (20 point) and highly
statistically significant improvements in the KCCQ sum-
mary score at 6 and 12 months. SF-12 physical scores
improved from baseline by at least 4.5 points in each
treatment group at 6 and 12 months. EQ-5D utilities
increased by 0.08 to 0.10 at 6 and 12 months with both
TAVR and AVR in the TF cohort; in the TA cohort, the
increase in EQ-5D scores was slightly less but nonetheless
significant for both treatment groups (0.04 to 0.06).
KCCQ summary scores were improved at 1 month in all
groups; however, the changes were modestly larger for
TAVR patients treated via the TF approach (mean increase,
23.7 points, 95% CI, 20.1 to 27.3; p  0.001) than for any
of the other groups (mean increases of 12.1 to 12.5 points).
KCCQ subscales and generic QOL measures were all
significantly improved at 1 month in the TF-TAVR group.
For the TF-AVR group and both TA groups, some but not
all secondary QOL measures were improved at 1 month.
Between-group comparisons. For the overall population,
TAVR resulted in more rapid improvement in the KCCQ
summary scale than AVR, with a significant benefit at 1
month (mean adjusted difference, 5.5; 95% CI: 1.2 to 9.8;
p  0.01) but no significant difference at either 6 months
Baseline Characteristics and Quality-of-Life ScoresTable 1 Baseline Characteristics and Quality-of-Life Scores
TF Cohort
TAVR (n  230) AVR (n
Demographic and clinical characteristics
Age, yrs 83.8 6.8 84.6
Male, % 60.4 55
STS risk score 11.8 3.2 11.5
Previous MI, % 27.4 24
Previous CABG, % 39.1 40
Cerebrovascular disease, % 22.6 22
Peripheral artery disease, % 35.1 35
COPD (oxygen dependent), % 8.3 7
LV ejection fraction, % 52.1 14.2 53.7
Frailty, % 16.0 16
Quality-of-life scores
KCCQ overall summary 39.3 21.7 43.8
KCCQ physical limitation 40.6 26.2 43.4
KCCQ symptoms 48.9 23.9 52.2
KCCQ quality of life 34.1 22.2 39.2
KCCQ social limitation 32.3 29.3 38.3
SF-12 physical summary 29.7 7.7 30.6
SF-12 mental summary 47.0 11.5 47.1
EQ-5D utilities 0.66 0.20 0.66
Values are mean  SD or %.
AVR  aortic valve replacement; CABG  coronary artery bypass graft; COPD  chronic obstruc
entricular; MI  myocardial infarction; SF-12  Medical Outcomes Study Short-Form 12; STS 
ransfemoral.(mean adjusted difference, 2.6; 95% CI: 6.7 to 1.6; p 0.22) or 12 months (mean adjusted difference, 0.5; 95%
CI:4.8 to 3.8; p 0.82). However, there was a significant
interaction between treatment assignment and access site,
particularly at the 1-month time point. Therefore, all QOL
analyses were performed separately for the TF and TA
cohorts.
The results from the growth curve models for the KCCQ
summary scale according to time point and access site are
summarized in Table 4 and Figure 1. At 1 month, in the TF
cohort, patients assigned to TAVR had significantly higher
(i.e., better) scores on the KCCQ summary scale compared
with patients assigned to surgical AVR (adjusted mean
difference between TAVR and AVR, 9.9 points; 95% CI,
4.9 to 14.9; p  0.001). In contrast, in the TA cohort,
1-month scores on the KCCQ summary scale tended to
favor AVR (mean difference, 5.8 points; 95% CI: 13.9
to 2.2; p  0.15). The interaction between treatment group
and access site was highly significant (p  0.001) at 1
month. At 6 and 12 months, there were no significant
differences in the KCCQ summary scores between patients
assigned to TAVR versus AVR in the TF cohort. In the TA
cohort, TAVR patients had lower mean KCCQ summary
scores at 6 months (adjusted difference, 7.9 points; p 
0.04), but there was no difference between the 2 treatments
at 12 months. The interactions between treatment group
and access site were not statistically significant at 6 or 12
months.
Results for each of the KCCQ subscales are summarized
TA Cohort
) p Value TAVR (n  98) AVR (n  84) p Value
0.24 82.6 7.0 83.2 5.9 0.56
0.30 51.0 59.5 0.25
0.23 11.8 3.7 11.7 3.2 0.76
0.42 27.6 36.9 0.18
0.73 51.0 56.0 0.51
0.99 36.7 29.8 0.32
0.90 61.2 62.7 0.84
0.74 11.2 7.1 0.35
0.25 53.1 12.4 53.4 11.0 0.86
0.89 14.3 18.1 0.49
0.03 40.3 22.1 46.2 19.8 0.06
0.29 40.9 24.1 48.6 23.2 0.03
0.15 49.9 23.7 55.5 22.1 0.10
0.02 34.7 26.9 40.4 22.3 0.13
0.04 34.6 30.0 40.5 26.9 0.18
0.28 29.4 7.4 31.7 8.5 0.06
0.96 46.6 11.4 48.7 9.6 0.18
0.77 0.67 0.19 0.72 0.17 0.07
monary disease; EQ-5D  EuroQol; KCCQ  Kansas City Cardiomyopathy Questionnaire; LV  left



















tive pulin Table 4 and Figure 1 as well, and paralleled those seen for
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Quality of Life After TAVR Versus AVR August 7, 2012:548–58the KCCQ summary scale. In the TF cohort, there was a
significant between-group difference favoring TAVR for all
4 KCCQ subscales at 1 month, but not at 6 or 12 months.
In the TA cohort, there were no significant differences
between TAVR and AVR on the KCCQ subscales at 1 or
12 months. At 6 months in the TA cohort, patients
assigned to TAVR had lower adjusted scores on the KCCQ
physical limitation (mean difference, 9.6 points; p 
0.04), QOL (mean difference, 8.4 points; p  0.06), and
symptom scales (mean difference, 13.2 points; p  0.001)
compared with AVR patients.
Results for both the SF-12 and EQ-5D utility scales
showed patterns similar to those for the disease-specific
scales (Fig. 2). In the TF cohort at 1 month, patients
assigned to TAVR demonstrated significantly higher scores
for the SF-12 physical (mean difference, 2.0; p  0.04),
SF-12 mental (mean difference, 5.4; p  0.001), and
EQ-5D utility scales (mean difference, 0.06; p  0.01)
scores, differences that were no longer apparent at either 6
Within-Group Comparisons: Transfemoral CohortTable 2 Within-Group Comparisons: Transfemoral Cohort
Scale/Time Point
TAVR
n Mean  vs. Baseline (95% CI)
KCCQ summary
1 month 197 23.7 (20.1 to 27.3)
6 months 183 29.8 (25.9 to 33.8)
12 months 165 28.7 (24.4 to 33.1)
KCCQ physical limitations
1 month 175 15.2 (10.4 to 20.0)
6 months 163 21.9 (17.2 to 26.7)
12 months 150 18.9 (13.5 to 24.2)
KCCQ total symptoms
1 month 196 20.4 (16.7 to 24.2)
6 months 182 24.8 (20.8 to 28.8)
12 months 164 24.8 (20.5 to 29.0)
KCCQ quality of life
1 month 196 31.5 (27.4 to 35.6)
6 months 181 38.2 (33.7 to 42.8)
12 months 165 38.1 (33.6 to 42.7)
KCCQ social limitation
1 month 159 24.7 (19.3 to 30.1)
6 months 149 31.8 (25.7 to 37.9)
12 months 140 33.3 (26.9 to 39.8)
SF-12 physical
1 month 184 5.0 (3.5 to 6.4)
6 months 172 6.7 (5.0 to 8.3)
12 months 155 6.3 (4.5 to 8.2)
SF-12 mental
1 month 184 4.3 (2.5 to 6.1)
6 months 172 5.1 (3.2 to 7.0)
12 months 155 5.0 (3.1 to 7.0)
EQ-5D utilities
1 month 192 0.08 (0.04 to 0.11)
6 months 176 0.10 (0.07 to 0.13)
12 months 160 0.09 (0.05 to 0.12)
CI  confidence interval; mo  month/months; other abbreviations as in Table 1.or 12 months. In the TA cohort, there were borderlinesignificant differences favoring AVR over TAVR for the
SF-12 physical (mean difference, 3.3; p  0.05) and
EQ-5D (mean difference, 0.065; p  0.05) scales at 6
months, whereas no significant differences between treat-
ment groups were observed at either 1 or 12 months. Of
note, when the growth curve models were repeated for the
as-treated population (n  607), the results were virtually
identical (Online Table 3). Likewise, imputing worst case
values for patients with missing data altered the results only
minimally (data not shown).
Categorical results. Figure 3 displays the distribution of
patients reporting pre-defined levels of improvement (or
worsening) on the KCCQ summary scale from baseline to
each follow-up time point. In the TF cohort, at 1-month
follow-up, the proportion of patients with at least a small
improvement from baseline was greater for the TAVR
group than for the AVR group (68.3% vs. 51.0%). By
ordinal logistic regression, the distributions of these
categorical change scores for the 2 treatment groups were
AVR
p Value n Mean  vs. Baseline (95% CI) p Value
0.001 157 12.1 (7.4 to 16.7) 0.001
0.001 139 26.9 (22.4 to 31.5) 0.001
0.001 136 26.8 (21.8 to 31.7) 0.001
0.001 132 3.2 (2.7 to 9.0) 0.29
0.001 127 20.2 (14.5 to 25.9) 0.001
0.001 117 14.4 (8.9 to 19.9) 0.001
0.001 157 12.8 (7.9 to 17.8) 0.001
0.001 139 24.3 (20.2 to 28.5) 0.001
0.001 133 23.3 (18.3 to 28.4) 0.001
0.001 154 18.9 (13.5 to 24.4) 0.001
0.001 137 34.0 (28.7 to 39.3) 0.001
0.001 130 37.3 (31.6 to 42.9) 0.001
0.001 115 12.0 (4.9 to 19.1) 0.001
0.001 115 28.3 (22.0 to 34.6) 0.001
0.001 103 30.6 (22.8 to 38.4) 0.001
0.001 149 2.6 (0.7 to 4.4) 0.006
0.001 134 7.2 (5.1 to 9.2) 0.001
0.001 127 6.1 (4.2 to 8.1) 0.001
0.001 149 0.3 (2.6 to 2.1) 0.82
0.001 134 4.0 (1.6 to 6.3) 0.001
0.001 127 4.7 (2.4 to 6.9) 0.001
0.001 154 0.02 (0.02 to 0.06) 0.43
0.001 136 0.09 (0.04 to 0.13) 0.001
0.001 129 0.08 (0.04 to 0.12) 0.001significantly different at 1 month (p  0.001) and 6
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was observed at 12 months. In contrast, among the TA
cohort, there were no differences in the distribution of
change categories between the TAVR and AVR groups
at any time point.
Discussion
In the PARTNER trial, the first randomized, controlled
trial comparing TAVR with AVR, we found that both
methods of valve replacement led to substantial improve-
ment in both disease-specific and general health status in
high-risk surgical candidates. In particular, outcomes at 12
months were similar when comparing TAVR and AVR
regardless of the TAVR access site. In addition, among
patients who were eligible for a TF approach, there were
both statistically significant and clinically relevant differ-
ences in health status and QOL at 1-month follow-up in
favor of TAVR. On the other hand, among patients who
were unsuitable for a TF procedure (and were therefore
Within-Group Comparisons: Transapical CohortTable 3 Within-Group Comparisons: Transapical Cohort
Scale/Time Point
TAVR
n Mean  vs. Baseline (95% CI)
KCCQ summary
1 month 77 12.5 (6.1 to 19.0)
6 months 71 23.8 (16.4 to 31.2)
12 months 66 29.6 (23.2 to 36.1)
KCCQ physical limitations
1 month 63 2.4 (4.9 to 9.7)
6 months 61 12.4 (4.3 to 20.5)
12 months 55 15.5 (7.4 to 23.6)
KCCQ total symptoms
1 month 77 12.9 (6.2 to 19.6)
6 months 70 16.6 (9.3 to 23.9)
12 months 64 23.1 (16.2 to 30.0)
KCCQ quality of life
1 month 77 22.1 (13.7 to 30.5)
6 months 71 32.1 (23.6 to 40.6)
12 months 65 41.7 (33.1 to 50.2)
KCCQ social limitation
1 month 61 6.9 (3.2 to 17.0)
6 months 58 27.4 (16.4 to 38.4)
12 months 50 34.2 (24.0 to 44.5)
SF-12 physical
1 month 76 2.8 (0.6 to 5.0)
6 months 70 5.2 (2.5 to 7.8)
12 months 66 7.1 (4.5 to 9.8)
SF-12 mental
1 month 76 0.8 (3.7 to 2.2)
6 months 70 3.3 (0.2 to 6.5)
12 months 66 3.6 (0.1 to 7.0)
EQ-5D utilities
1 month 74 0.02 (0.08 to 0.03)
6 months 66 0.04 (0.02 to 0.11)
12 months 61 0.06 (0.01 to 0.12)
Abbreviations as in Tables 1 and 2.treated via the TA approach to TAVR), health status wasnot better at any time point after TAVR than after AVR.
Moreover, there were trends and, in some cases, borderline
statistically significant differences in favor of AVR both at 1
and 6 months.
The improvements in health status observed 6 and 12
months after both TAVR and AVR were great, highly
statistically significant, and clinically meaningful. By 6
months, KCCQ summary scores had generally increased 25
to 30 points, indicating very substantial benefit because
changes of as little as 5 points on this scale were previously
shown to correlate with changes in survival and medical care
costs in heart failure patients (15,16). Improvements in
generic measures, in particular, the SF-12 physical summary
score (5 to 7 points at 6 and 12 months) were also 2 to 3
times greater than the 2.5-point threshold generally consid-
ered to indicate a clinically relevant change (19,20). These
results are all the more remarkable when one considers that
the PARTNER trial population represents patients with the
highest 5% of surgical risk, based on baseline Society of
AVR
p Value n Mean  vs. Baseline (95% CI) p Value
0.001 61 12.5 (5.5 to 19.5) 0.0007
0.001 56 27.3 (21.0 to 33.7) 0.001
0.001 59 21.6 (13.8 to 29.4) 0.001
0.52 51 1.7 (7.7 to 11.1) 0.72
0.003 52 17.3 (9.6 to 25.0) 0.001
0.001 54 11.7 (3.2 to 20.3) 0.008
0.001 60 12.1 (5.6 to 18.5) 0.001
0.001 55 25.6 (19.2 to 32.0) 0.001
0.001 59 18.7 (11.2 to 26.3) 0.001
0.001 61 20.9 (13.1 to 28.7) 0.001
0.001 56 34.8 (27.4 to 42.2) 0.001
0.001 58 29.5 (20.7 to 38.2) 0.001
0.18 46 2.8 (7.9 to 13.4) 0.60
0.001 48 28.6 (19.1 to 38.1) 0.001
0.001 47 22.8 (11.0 to 34.7) 0.001
0.01 61 0.5 (2.1 to 3.0) 0.71
0.001 57 7.0 (4.4 to 9.6) 0.001
0.001 58 4.5 (1.2 to 7.8) 0.008
0.60 61 1.7 (1.4 to 4.8) 0.27
0.04 57 3.7 (1.0 to 6.3) 0.008
0.04 58 3.9 (0.6 to 7.2) 0.02
0.44 58 0.01 (0.04 to 0.06) 0.74
0.20 52 0.06 (0.01 to 0.12) 0.03
0.03 54 0.05 (0.02 to 0.12) 0.14Thoracic Surgeon scores (10).
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and, more recently, TAVR (5–7,24–28) improve health
status and QOL compared with baseline for patients with
severe AS. Most of these studies compared scores on the
SF-12, SF-36, or the Minnesota Living With Heart Failure
Questionnaire from baseline to 1 or 2 follow-up time points
and included patients treated predominantly via transarterial
TAVR approaches. Our results add to this literature by
examining the time course of health status improvement
over the first year after intervention in greater detail, and,
more importantly, by comparing the benefits of TAVR with
those of standard surgical AVR as a function of both time
and TAVR access site.
The findings observed in the TF cohort of the PARTNER
trial are consistent with the more rapid recovery that would
be expected when comparing a percutaneous procedure with
traditional valve replacement surgery and are consistent with
previously reported benefits of TAVR on New York Heart






1 month 9.9 (4.9 to 14.9)
6 months 0.5 (5.3 to 4.4)
12 months 1.2 (6.3 to 3.9)
KCCQ physical limitations
1 month 10.9 (4.5 to 17.4)
6 months 0.5 (6.3 to 5.4)
12 months 2.3 (3.9 to 8.5)
KCCQ total symptoms
1 month 6.6 (1.9 to 11.4)
6 months 2.1 (6.7 to 2.5)
12 months 1.1 (5.8 to 3.7)
KCCQ quality of life
1 month 9.8 (4.0 to 15.6)
6 months 0.3 (5.2 to 5.7)
12 months 1.9 (7.6 to 3.8)
KCCQ social limitation
1 month 10.6 (3.0 to 18.2)
6 months 2.9 (10.1 to 4.3)
12 months 2.9 (10.5 to 4.8)
SF-12 physical
1 month 2.0 (0.1 to 3.9)
6 months 0.9 (3.0 to 1.2)
12 months 0.4 (2.8 to 2.0)
SF-12 mental
1 month 5.4 (3.1 to 7.7)
6 months 1.2 (1.0 to 3.5)
12 months 0.4 (1.8 to 2.7)
EQ-5D utilities
1 month 0.06 (0.02 to 0.10)
6 months 0.01 (0.03 to 0.05)
12 months 0.03 (0.02 to 0.07)
Abbreviations as in Tables 1 and 2.Association functional class and 6-min walk distance at 30days (10). Although most of the health status measures had
already begun to improve by 1 month in the AVR group,
substantial additional improvement was observed at both 6
and 12 months. In contrast, improvement was more rapid
for TAVR patients treated via the TF approach, such that
the extent of improvement by 1 month was nearly as great
as that seen at later time points. As a result, direct
between-group comparisons strongly favored TAVR at 1
month in the TF subgroup.
On the other hand, among TA patients (who were, by
definition, anatomically unsuitable for a TF approach),
there was no short-term advantage for TAVR over AVR in
either disease-specific or generic health status. This result
was somewhat unexpected, given that TAVR via the TA
approach involves a smaller incision than median sternot-
omy and avoids the need for cardiopulmonary bypass. The
explanation for this result is currently unknown. Previous
research comparing cardiothoracic surgery performed using




TAVR-AVR (95% CI) p Value
0.001 5.8 (13.9 to 2.2) 0.15
0.85 7.9 (15.7 to0.2) 0.04
0.64 0.8 (7.2 to 8.8) 0.85
0.001 5.8 (16.3 to 4.8) 0.28
0.41 9.6 (18.9 to -0.2) 0.04
0.47 4.1 (13.8 to 5.6) 0.41
0.006 5.1 (12.8 to 2.5) 0.19
0.37 13.2 (20.5 to5.9) 0.001
0.66 2.3 (9.7 to 5.2) 0.55
0.001 4.7 (13.9 to 4.5) 0.32
0.93 8.4 (17.0 to 0.2) 0.06
0.50 4.8 (4.0 to 13.7) 0.28
0.007 5.8 (17.9 to 6.4) 0.35
0.43 3.8 (15.1 to 7.5) 0.51
0.46 6.1 (5.9 to 18.1) 0.32
0.04 0.3 (2.7 to 3.3) 0.85
0.41 3.3 (6.7 to 0.0) 0.05
0.77 0.2 (3.5 to 3.8) 0.92
0.001 4.3 (7.9 to0.8) 0.02
0.28 2.5 (6.0 to 1.0) 0.16
0.69 2.5 (5.9 to 0.9) 0.15
0.008 0.06 (0.13 to 0.02) 0.13
0.57 0.07 (0.13 to 0.0) 0.05
0.23 0.05 (0.12 to 0.02) 0.17GrowLongi
,thoracotomy incisions and that performed using median
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ery from thoracotomy incisions is faster or easier. In fact, in
some studies, ratings of pain during the early postoperative
period have actually been worse with thoracotomy than
median sternotomy, results that have been hypothesized to
relate to delayed effects of rib spreading and/or respiratory
motion (29–31). Careful attention to pain control, such as
with epidural anesthesia, could potentially mitigate these
Figure 1 Between-Group Differences: KCCQ
The difference between transcatheter aortic valve replacement (TAVR) and aortic v
all summary (A) and subscale (B to E) scores, based on longitudinal growth curve
transfemoral (TF) cohort (blue circles) and the transapical (TA) cohort (yellow squ
site (TF or TA) are shown. Error bars denote 95% confidence intervals.issues in the future.Another potential explanation for the lack of benefit with
TA-TAVR versus AVR could relate to differences in either
the number or nature of major complications for the 2
procedures. Of note, the rate of major strokes in the TA
cohort was somewhat higher for TAVR than AVR at both
30 days and 1 year (10), but the absolute magnitude of these
differences was small. Other adverse events were similar
between groups except for major bleeding, which was more
placement (AVR) on the Kansas City Cardiomyopathy Questionnaire (KCCQ) over-
ls, at 1-, 6-, and 12-month follow-up. Results are reported separately for the
p Values for the interaction (int) between treatment (TAVR vs. AVR) and accessalve re
mode
ares).common after AVR (8.7% vs. 17.9%, p  0.05). Based on
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complication rates are solely responsible for the lack of
benefit in health status outcomes with the TA approach.
Finally, it is possible that the apical puncture and repair
performed for TA-TAVR could conceivably result in
greater impairment of left ventricular function than AVR
Figure 2 Between-Group Differences: Generic Scales
The difference between TAVR and AVR on the Medical Outcomes Study Short-
Form 12 (SF-12) (A and B) and Euro-Qol (EQ-5D) (C) scores are shown based
on longitudinal growth curve models at 1, 6, and 12 months. Results are
reported separately for the TF cohort (blue circles) and the TA cohort (yellow
squares). Abbreviations as in Figure 1.leading to more functional limitations.Study limitations. In interpreting these results, it is also
important to recognize that the PARTNER trial represents
a very early experience with TAVR procedures in the
United States, particularly for the TA approach. Among the
14 sites at which TA-TAVR procedures were performed in
the PARTNER trial, the median number of procedures
per center was 4 (range, 1 to 20), with more than 10
procedures performed at only 5 sites. Like most complex
cardiac procedures, TAVR has a well-documented learn-
ing curve, and the site-level volume of TA procedures
done in the PARTNER trial was clearly below the level
at which learning curve effects begin to dissipate (32).
Thus, many aspects of the care of TAVR patients are
likely to improve with time and experience. In addition,
far fewer total patients were randomized within the TA
subgroup compared with the TF subgroup, such that the
TA subgroup had less statistical power for all trial
endpoints.
Figure 3 Categorial Results
The proportions of TAVR and AVR patients achieving pre-specified categorical
levels of change from baseline to 1-, 6-, and 12-month follow-up according to
the KCCQ overall summary score. Results are shown separately for the TF
cohort (A) and the TA cohort (B). p Values are based on ordinal logistic regres-
sion. Abbreviations as in Figure 1.
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for example, patients with the poorest health status were the
ones most likely not to complete questionnaires. Because we
observed slightly more missing data in the AVR group than
the TAVR group, and the rates of death and most major
complications were similar between groups, this seems like
an unlikely explanation for our findings. Moreover, a sen-
sitivity analysis in which we imputed worst case values for
those patients with missing follow-up data did not alter any
of our main results.
The PARTNER trial was unblinded, and patients ran-
domized to TAVR could have experienced subjective im-
provements in some aspects of their health status based on
expectations that the new procedure was less invasive than
surgical AVR. It would not have been feasible to conduct
the PARTNER trial in a blinded fashion, however, and
consequently there is no definitive way to address this
theoretical concern. Finally, our analysis was also limited to
12 months of follow-up. Although the frequent sampling of
patients during the first year provided rich information
about the time course of improvement during this critical
period, our analysis does not provide information about any
potential long-term differences in health status that could
arise as a consequence of differences in long-term device
performance or other factors.
Conclusions
The PARTNER trial has confirmed that correction of
severe AS either by TAVR or AVR leads to very great
improvement in patient-reported symptoms, functional sta-
tus, and QOL over the first year of follow-up, even in a
population selected for high surgical risk. The more rapid
recovery from TAVR via the TF approach is associated with
short-term benefits in health status, which may be impor-
tant from the patient’s perspective. On the other hand, for
patients who were ineligible for a TF approach (and thus
underwent TAVR via the TA approach), in this early
experience with TAVR procedures, there was no evidence
of health status benefits either in the short or medium term.
Future studies are necessary to determine whether ongoing
improvements in procedural techniques or ancillary care
lead to differences in recovery for TAVR patients treated via
the TA approach.
Reprint requests and correspondence: Dr. David J. Cohen, Saint
Luke’s Mid America Heart Institute, University of Missouri-
Kansas City School of Medicine, 4401 Wornall Road, Kansas
City, Missouri 64111. E-mail: dcohen@saint-lukes.org.
REFERENCES
1. Schwarz F, Baumann P, Manthey J, et al. The effect of aortic valve
replacement on survival. Circulation 1982;66:1105–10.
2. Khan JH, McElhinney DB, Hall TS, Merrick SH. Cardiac valve
surgery in octogenarians: improving quality of life and functional
status. Arch Surg 1998;133:887–93.3. Sundt TM, Bailey MS, Moon MR, et al. Quality of life after aortic
valve replacement at the age of 80 years. Circulation 2000;102:
III70–4.
4. Cribier A, Eltchaninoff H, Tron C, et al. Treatment of calcific aortic
stenosis with the percutaneous heart valve: mid-term follow-up from
the initial feasibility studies: the French experience. J Am Coll Cardiol
2006;47:1214–23.
5. Svensson LG, Dewey T, Kapadia S, et al. United States feasibility
study of transcatheter insertion of a stented aortic valve by the left
ventricular apex. Ann Thorac Surg 2008;86:46–54.
6. Bekeredjian R, Krumsdorf U, Chorianopoulos E, et al. Usefulness of
percutaneous aortic valve implantation to improve quality of life in
patients 80 years of age. Am J Cardiol 2010;106:1777–81.
7. Ussia GP, Mule M, Barbanti M, et al. Quality of life assessment after
percutaneous aortic valve implantation. Eur Heart J 2009;30:1790–6.
8. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve
implantation for aortic stenosis in patients who cannot undergo
surgery. N Engl J Med 2010;363:1597–607.
9. Reynolds MR, Magnuson EA, Lei Y, et al. Health related quality
of life after transcatheter aortic valve replacement in inoperable
patients with severe aortic stenosis. Circulation 2011;124:1964 –72.
10. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical
aortic-valve replacement in high-risk patients. N Engl J Med 2011;
364:2187–98.
11. Moat NE, Ludman P, de Belder MA, et al. Long-term outcomes after
transcatheter aortic valve implantation in high-risk patients with severe
aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter
Aortic Valve Implantation) Registry. J Am Coll Cardiol 2011;58:
2130–8.
12. Spertus JA, Tooley J, Jones P, et al. Expanding the outcomes in clinical
trials of heart failure: the quality of life and economic components of
the EPHESUS (EPlerenone’s neuroHormonal Efficacy and Survival
Study). Am Heart J 2002;143:636–42.
13. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and
evaluation of the Kansas City Cardiomyopathy Questionnaire: a new
health status measure for heart failure. J Am Coll Cardiol 2000;35:
1245–55.
14. Spertus J, Peterson E, Conard MW, et al. Monitoring clinical changes
in patients with heart failure: a comparison of methods. Am Heart J
2005;150:707–15.
15. Chan PS, Soto G, Jones PG, et al. Patient health status and costs in
heart failure: insights from the eplerenone post-acute myocardial
infarction heart failure efficacy and survival study (EPHESUS). Cir-
culation 2009;119:398–407.
16. Soto GE, Jones P, Weintraub WS, Krumholz HM, Spertus JA.
Prognostic value of health status in patients with heart failure after
acute myocardial infarction. Circulation 2004;110:546–51.
17. Ware J, Kosinski M, Keller SD. A 12-item short-form health survey:
construction of scales and preliminary tests of reliability and validity.
Med Care 1996;34:220–33.
18. The EuroQol Group. Euro-Qol: a new facility for measurement of
health-related quality of life. Health Policy 1990;16:199–208.
19. Ware J, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B,
Maruish ME. Determining important differences in scores. In: User’s
Manual for the SF-36v2 Health Survey. Lincoln, RI: QualityMetric
Incorporated, 2007.
20. Wyrwich KW, Spertus JA, Kroenke K, Tierney WM, Babu AN,
Wolinsky FD. Clinically important differences in health status for
patients with heart disease: an expert consensus panel report. Am
Heart J 2004;147:615–22.
21. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health
states: development and testing of the D1 valuation model. Med Care
2005;43:203–20.
22. Ware JE Jr., Kosinski M, Turner-Bowker DM, Gandek B. How to
Score Version 2 of the SF-12 Health Survey (With a Supplement
Documenting Version 1). Lincoln, RI: QualityMetric Incorporated,
2002.
23. Jennrich RI, Schluchter MD. Unbalanced repeated-measures models
with structured covariance matrices. Biometrics 1986;42:805–20.
24. Georgiadou P, Kontodima P, Sbarouni E, et al. Long-term quality of
life improvement after transcatheter aortic valve implantation. Am
Heart J 2011;162:232–7.
558 Reynolds et al. JACC Vol. 60, No. 6, 2012
Quality of Life After TAVR Versus AVR August 7, 2012:548–5825. Gotzmann M, Bojara W, Lindstaedt M, et al. One-year results of
transcatheter aortic valve implantation in severe symptomatic aortic
valve stenosis. Am J Cardiol 2011;107:1687–92.
26. Gotzmann M, Hehen T, Germing A, et al. Short-term effects of
transcatheter aortic valve implantation on neurohormonal activation,
quality of life and 6-minute walk test in severe and symptomatic aortic
stenosis. Heart 2010;96:1102–6.
27. Krane M, Deutsch MA, Bleiziffer S, et al. Quality of life among
patients undergoing transcatheter aortic valve implantation. Am
Heart J 2010;160:451–7.
28. Ussia GP, Barbanti M, Cammalleri V, et al. Quality-of-life in elderly
patients one year after transcatheter aortic valve implantation for severe
aortic stenosis. EuroIntervention 2011;7:573–9.
29. Diegeler A, Walther T, Metz S, et al. Comparison of MIDCAP
versus conventional CABG surgery regarding pain and quality of life.
Heart Surg Forum 1999;2:290–5; discussion 295–6.30. Grossi EA, Zakow PK, Ribakove G, et al. Comparison of post-
operative pain, stress response, and quality of life in port access vs.
standard sternotomy coronary bypass patients. Eur J Cardiothorac
Surg 1999;16 Suppl 2:S39–42.
31. Walther T, Falk V, Metz S, et al. Pain and quality of life after
minimally invasive versus conventional cardiac surgery. Ann Thorac
Surg 1999;67:1643–7.
32. Alli OO, Booker JD, Lennon RJ, Greason KL, Rihal CS, Holmes DR
Jr. Transcatheter aortic valve implantation: assessing the learning
curve. J Am Coll Cardiol Intv 2012;5:72–79.
Key Words: aortic stenosis y AVR y quality of life y TAVR.
APPENDIXFor supplemental tables, please see the online version of this article.
